2C-tBu
2C-tBu, or 2C-t-Bu, also known as 4-tert-butyl-2,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative serotonergic psychedelic of the phenethylamine and 2C families.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
2C-tBu, or 2C-t-Bu, also known as 4-tert-butyl-2,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative serotonergic psychedelic of the phenethylamine and 2C families.
Use and effects
The active dose of 2C-tBu in humans is >5 mg orally per Daniel Trachsel and its duration is unknown. Initial tests with 7 mg and with 10 mg (as 5 mg plus 5 mg 2 hours apart) orally produced no psychedelic effects in humans, but instead induced a pronounced and long-lasting tiredness.
It was hypothesized by Daniel Trachsel and colleagues that 2C-tBu might be a serotonin 5-HT 2A receptor antagonist and might thereby be hypnotic, but it was instead shown to be an agonist in subsequent studies.
Pharmacodynamics
2C-tBu is a potent serotonin 5-HT 2A receptor agonist (K i = 9.9–35 nM, = 4.2 nM) and also binds to the serotonin 5-HT 2C receptor (K i = 7–24 nM). The drug produces a robust head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It also produces hyperlocomotion in rodents.
Analogues
Analogues of 2C-tBu include 2C-Bu, 2C-iBu, 2C-sBu, and DOTB, among others.
History
2C-tBu was first described in the scientific literature by Daniel Trachsel and colleagues in 2013.
Canada
2C-tBu is a controlled substance in Canada under phenethylamine blanket-ban language.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371213299 under CC BY-SA 4.0; modifications have been made.